Phosphatase and tensin homologue:a therapeutic target for SMA

Spinal muscular atrophy(SMA)is one of the most common juvenile neurodegenerative diseases,which can be associated with child mortality.SMA is caused by a mutation of ubiquitously expressed gene,Survival Motor Neuron1(SMN1),leading to reduced SMN protein and the motor neuron death.The disease is incurable and the only therapeutic strategy to follow is to improve the expression of SMN protein levels in motor neurons.Significant numbers of motor neurons in SMA mice and SMA cultures are caspase positive with condensed nuclei,suggesting that these cells are prone to a process of cell death called apoptosis.Searching for other potential molecules or signaling pathways that are neuroprotective for central nervous system(CNS)insults is essential for widening the scope of developmental medicine.PTEN,a Phosphatase and Tensin homologue,is a tumor suppressor,which is widely expressed in CNS.PTEN depletion activates anti-apoptotic factors and it is evident that the pathway plays an important protective role in many neurodegenerative disorders.It functions as a negative regulator of PIP3/AKT pathway and thereby modulates its downstream cellular functions through lipid phosphatase activity.Moreover,previous reports from our group demonstrated that,PTEN depletion using viral vector delivery system in SMN delta7 mice reduces disease pathology,with significant rescue on survival rate and the body weight of the SMA mice.Thus knockdown/depletion/mutation of PTEN and manipulation of PTEN medicated Akt/PKB signaling pathway may represent an important therapeutic strategy to promote motor neuron survival in SMA.